In this case study, Xstrahl 150 was used to treat two patients with Cutaneous Squamous Cell Carcinoma.
Cutaneous Squamous Cell Carcinoma Case Study
read more
Squamous Cell Carcinoma
Xstrahl 150 Used as System of Choice for Australian Case Study Reviews
With the rates of skin cancers ever increasing, especially in places with high sun prevalence, treatment of these conditions can cause not only a demand on resources, but there is a lack of unified response and the best way to treat. This is why Prof. Gerald Fogarty...
Xstrahl in Action: Xstrahl 200 Used for Research into Clinical Response Following Superficial Radiation Therapy of SCCs
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and arises from abnormal growth in the squamous cells of the skin’s outermost layer due to cumulative exposure to ultraviolet radiation. Without treatment, cSCC can be...
Xstrahl in Action: Xstrahl 200 Used for Treatment of Advanced and Inoperable Bowen’s Disease
Bowen’s disease is a type of squamous cell carcinoma (SCC) in situ of the skin usually characterized by slow-growing, red and scaly patches of skin. Bowen’s disease can be symptomatic and can progress to invasive SCC causing morbidity and even mortality. In their...
USA Today: New technology helps treat skin cancer without surgery
The face of skin cancer is changing, as awareness is at an all-time high and medical technology is rapidly advancing. Still, the Skin Cancer Foundation reports that more than 5.4 million cases of nonmelanoma skin cancer are treated each year in the U.S., affecting 3.3...
Xstrahl in Action: ATR kinase inhibitor enables T cell-dependent antitumor activity
DNA-damaging chemotherapy and radiation therapy are integrated into the treatment paradigm of the majority of cancer patients. Recently, immunotherapy that targets the immunosuppressive interaction between programmed death 1 (PD-1) and its ligand PD-L1 has been...
Xstrahl Introduces One-Stop Shop Treatment System for Non-Melanoma Skin Cancer
April 24th, 2019 New 150kV superficial treatment system spotlighted on Xstrahl booth (No. 3420) at ESTRO show in Milan, Italy, April 26th-29th Xstrahl Medical, global leader in superficial radiotherapy devices to treat non-melanoma skin cancer and dermatological...
Xstrahl in Action: Palliative radiotherapy for skin malignancies
According to the American Academy of Dermatology, it is estimated that non-melanoma skin cancer, including basal cell carcinoma and squamous cell carcinoma, affects more than 3 million Americans a year and 178,560 new cases of melanoma, including 91,270 invasive, will...
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation
DNA damaging chemotherapy and radiation therapy are integrated into the treatment paradigm of the majority of cancer patients. Recently, immunotherapy that targets the immunosuppressive interaction between Programmed Death 1 (PD-1) and its ligand PD-L1 has been...
Contact Us